-
1. HIGHLIGHTS OF PRESCRIBING INFORMATION Continue treatme…
Link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf
Description: WEBFor patients weighing <77 kg (<170 lbs) OR with a platelet count < 150,000/μL, the recommended dose is 200 mg taken orally once daily. (2.2) For patients …
-
2. Zejula (niraparib) capsules - GSKpro
Link: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Zejula_Capsules/pdf/ZEJULA-CAPSULES-PI-PIL.PDF
Description: WEBNiraparib solubility is pH independent below the pKa of 9.95, with an aqueous free base solubility of 0.7 mg/mL to 1.1 mg/mL across the physiological pH …
-
3. Zejula Product Monograph - GSK
Link: https://ca.gsk.com/media/6229/zejula_pm_en.pdf
Description: WEBZEJULA (niraparib capsules and tablets) Page 8 of 47 recommended starting dose of niraparib is 200 mg once daily (see 10.3 Pharmacokinetics). Monitor …
-
4. Reference ID: 4075456 - Food and Drug Administration
Link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf
Description: WEBZEJULATM (niraparib) capsules, for oral use Initial U.S. Approval: 2017 INDICATIONS AND USAGE ZEJULA is a poly(ADP-ribose) polymerase (PARP) …
-
5. Niraparib (ZEJULA) | FDA
Link: https://www.fda.gov/drugs/resources-information-approved-drugs/niraparib-zejula
Description: WEBOn March 27, 2017 , the U.S. Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the …
